Bio-Techne Corporation Q2 2026 Earnings Recap

Bio-Techne's Q2 FY2026 results showed flat organic revenue growth due to external market pressures, though large pharma demand remained strong and profitability improved, reflecting solid operational execution.

Key Takeaways

• Organic revenue growth was flat, impacted by timing effects from FDA Fast Track designations for key cell therapy customers.
• Adjusted operating margins expanded by 100 basis points year-over-year to 31.1%, demonstrating a focus on productivity and cost management.
• Large pharma revenue grew in low double digits, while emerging biotech customers faced mid-single-digit declines amid challenging funding conditions.
• Significant growth in spatial biology bookings and a strong performance across Asia, particularly China, highlight emerging opportunities.
• Core growth verticals now account for 47% of total revenue, with an upper teens CAGR over the past five years, driving future potential.